Trametinib Monotherapy in the Treatment of Pediatric Refractory/Relapse Langerhans Cell Histiocytosis
Overall, TRA was effective and safe in the treatment of patients with refractory/relapse LCH, offering a convenient therapeutic alternative.
Authors
- Zishi Fang (ORCID: https://orcid.org/0009-0005-2765-9635)
- R X Zhang (ORCID: https://orcid.org/0009-0008-8075-9899)
- Tianyou Wang (ORCID: https://orcid.org/0000-0002-8641-3046)
- Chenxin Zhou
- Yunze Zhao
- Wenqian Wang (ORCID: https://orcid.org/0000-0003-2925-4306)
- Zhigang Li (ORCID: https://orcid.org/0000-0003-0378-3496)
- Dong Wang
- Jian Ge
- Lei Cui
Institutions
- Ministry of Education of the People's Republic of China (CN)
- Capital Medical University (CN)
- Beijing Children’s Hospital (CN)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1002/1545-5017.70162
- Primary Topic
- Histiocytic Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00